Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cortexyme Inc (CRTX)

Cortexyme Inc (CRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,794
  • Shares Outstanding, K 30,151
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,950 K
  • 60-Month Beta 1.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.55
Trade CRTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.23
  • Most Recent Earnings -0.72 on 05/10/22
  • Next Earnings Date 08/08/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 78.22%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.71
  • Low Estimate -0.77
  • Prior Year -0.74
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7821 +9.42%
on 07/28/22
2.5800 -24.42%
on 07/07/22
-0.3100 (-13.72%)
since 06/29/22
3-Month
1.7821 +9.42%
on 07/28/22
4.0357 -51.68%
on 05/03/22
-1.7100 (-46.72%)
since 04/29/22
52-Week
1.7821 +9.42%
on 07/28/22
40.6600 -95.20%
on 08/10/21
-16.7267 (-89.56%)
since 07/29/21

Most Recent Stories

More News
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate...

CRTX : 1.9500 (+2.63%)
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1...

CRTX : 1.9500 (+2.63%)
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy...

CRTX : 1.9500 (+2.63%)
Cortexyme Appoints June Bray to its Board of Directors

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and...

CRTX : 1.9500 (+2.63%)
Cortexyme Appoints Dr. Philip Low to Its Board of Directors

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment...

CRTX : 1.9500 (+2.63%)
Cortexyme Successfully Completes Acquisition of Novosteo

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion...

CRTX : 1.9500 (+2.63%)
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company...

CRTX : 1.9500 (+2.63%)
Cortexyme Announces Agreement to Acquire Novosteo

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement...

CRTX : 1.9500 (+2.63%)
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX

WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations...

CRTX : 1.9500 (+2.63%)
Notable Tuesday Option Activity: CRTX, XPOF, SPNS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cortexyme Inc , where a total of 3,250 contracts have traded so far, representing approximately...

CRTX : 1.9500 (+2.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The company's drug candidate consists of COR388 which is in clinical stage. Cortexyme Inc. is based in San Francisco, United States....

See More

Key Turning Points

3rd Resistance Point 2.1033
2nd Resistance Point 2.0367
1st Resistance Point 1.9933
Last Price 1.9500
1st Support Level 1.8833
2nd Support Level 1.8167
3rd Support Level 1.7733

See More

52-Week High 40.6600
Fibonacci 61.8% 25.8086
Fibonacci 50% 21.2211
Fibonacci 38.2% 16.6335
Last Price 1.9500
52-Week Low 1.7821

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar